GleamWall
中文EN

VTGN Vistagen Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1411685 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY230.4%
TTM net income YoY5.3%
TTM EPS YoY29.7%
Revenue 3-yr CAGR43.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,541.9%
Net margin-2,474.5%
FCF margin—
EBITDA margin-2,533.2%

Returns

ROE-144.9%
ROA-113.0%
ROIC (approx.)-1,250.0%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.64x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio3.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue$138,000$1.48M$465,000$303,000$258,000$244,000-$15,000$234,000
R&D expense$6.55M$10.91M$13.06M$14.22M$15.91M$11.68M$10.21M$11.30M
SG&A expense$4.52M$3.92M$4.12M$5.63M$4.40M$4.37M$4.27M$4.05M
Operating income-$10.94M-$13.35M-$16.72M-$19.55M-$20.05M-$15.80M-$14.49M-$15.12M
Pretax income-$10.74M-$13.03M-$16.27M-$18.90M-$19.42M-$15.10M-$13.63M-$14.09M
Income tax$0$0$7,000$0$0$0$0$0
Net income-$10.74M-$13.03M-$16.27M-$18.90M-$19.42M-$15.10M-$13.63M-$14.09M
EBITDA-$10.89M-$13.30M-$16.66M-$19.49M-$20.00M-$15.76M-$14.46M-$15.08M
EPS (basic)-0.24-0.30—-0.45-0.54-0.47—-0.46
EPS (diluted)-0.24-0.30—-0.45-0.54-0.47—-0.46
Weighted avg. shares (diluted)44.44M42.98M—42.23M35.75M31.93M—30.71M
Balance sheet
Cash & equivalents$10.89M$16.99M$30.79M$47.37M$62.79M$48.98M$67.13M$74.72M
Short-term investments$9.14M$14.74M$14.61M$14.40M$14.39M$14.20M$13.35M$13.85M
Current assets$22.29M$34.31M$46.94M$63.24M$78.93M$66.72M$82.08M$89.94M
PP&E, net$325,000$375,000$427,000$480,000$516,000$530,000$476,000$428,000
Total assets$23.42M$35.74M$48.56M$65.06M$80.93M$68.92M$84.34M$92.31M
Current liabilities$8.43M$11.19M$12.79M$13.53M$13.64M$11.15M$12.61M$9.62M
Total liabilities$8.43M$11.26M$13.04M$14.14M$14.59M$12.16M$13.95M$11.19M
Shareholders' equity$14.99M$24.48M$35.52M$50.92M$66.34M$56.77M$70.39M$81.12M
Cash flow statement
Operating cash flow-$12.16M-$14.71M-$16.20M-$17.63M-$13.76M-$18.85M-$10.06M-$10.28M
Investing cash flow$5.71M$0-$99,000$104,000-$94,000-$788,000$527,000-$422,000
Financing cash flow$351,000$909,000-$283,000$2.11M$27.65M$1.49M$1.95M$1.17M
Depreciation & amortization$50,000$52,000$52,000$54,000$53,000$40,000$40,000$39,000
Stock-based compensation$907,000$991,000$889,000$1.10M$1.10M$916,000$963,000$1.08M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.